The Relationship among Pore-Size Ratings, Bubble Points, and Porosity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Relationship among Pore-Size Ratings, Bubble Points, and Porosity


Pharmaceutical Technology


35. EMEA CPMP/QMP/489/95, Note For Guidance in Manufacture of the Finished Dosage Form, 5-6 (April reissue 1996).

36. J.P. Agalloco, "Guest Editorial: It Just Doesn't Matter," PDA J. Pharm. Sci. Technol. 52 (4), 149–150 (1998).

37. Society of Automotive Engineers (SAE), Bubble Point Test. Method, Aerospace Recommended Practice ARP-901 (1968).

38. M.W. Jornitz and T.H. Meltzer, Filtration Handbook: Integrity Testing (PDA, Bethesda, MD; DHI Publishing, River Grove, IL, 2003).

39. D.B. Pall, "Quality Control of Absolute Bacteria Removal Filters," Bull. PDA 29, 192–212 (1975).

40. A. Baszkin, D.J. Lyman, and T.H. Meltzer, "Theoretical Considerations of BubblePoint Measurement: Solid/Liquid Wetting Interaction," Pharm. Technol. Int. 2 (l), 22–31 (1978).

41. P.R. Johnston and T.H. Meltzer, "Comments on Organism Challenge Levels in Sterilizing-Filter Efficiency Testing," Pharm. Technol. 3 (11), 66–70, 110 (1979).

42. W.J. Elford, "The Principles of Ultrafiltration as Applied in Biological Studies," Proceedings of the Royal Society, 112B (London, UK, 1933), pp. 384–406.

43. A.R. Reti, "An Assessment of Test Criteria in Evaluating the Performance and Integrity of Sterilizing Filters," Bull. Paren Drug Assoc. 3l (4), 187–194 (1977).

44. D.C. Grant and J.G. Zahke, "Sieving Capture of Particles by MicroporousMembrane Filters From Clean Liquids," Swiss Contamin. Control 3 (4a), 160–164 (1990).

45. M.L. Roberts and D.J. Valazquez, "Characterizing the Rating and Performance of Membrane Filter for Liquid Applications Using Latex Spheres," Swiss Contam. Quarterly 3, 71–74 (1990).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here